Autolus Therapeutics’ (AUTL) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Autolus Therapeutics (NASDAQ:AUTL) in a report issued on Monday morning,Benzinga reports. The firm currently has a $10.00 target price on the stock. HC Wainwright also issued estimates for Autolus Therapeutics’ Q2 2026 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.21) EPS, Q4 2026 earnings at ($0.19) EPS, FY2026 earnings at ($0.88) EPS, FY2027 earnings at ($0.74) EPS, FY2028 earnings at ($0.83) EPS, FY2029 earnings at ($0.69) EPS and FY2030 earnings at ($0.23) EPS.

Several other analysts have also recently commented on AUTL. Weiss Ratings cut Autolus Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, July 31st. Jefferies Financial Group upgraded shares of Autolus Therapeutics to a “strong-buy” rating in a report on Monday, April 20th. Needham & Company LLC restated a “buy” rating and set a $10.00 price target on shares of Autolus Therapeutics in a report on Thursday, April 9th. Finally, Wall Street Zen upgraded shares of Autolus Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 13th. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Autolus Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $8.75.

Autolus Therapeutics Trading Down 2.6%

Shares of AUTL opened at $1.90 on Monday. The company has a market capitalization of $505.70 million, a PE ratio of -1.74 and a beta of 2.07. Autolus Therapeutics has a 12 month low of $1.18 and a 12 month high of $2.52. The stock’s 50-day moving average price is $1.58 and its two-hundred day moving average price is $1.53.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.02. Autolus Therapeutics had a negative return on equity of 128.59% and a negative net margin of 311.98%.The company had revenue of $26.22 million during the quarter, compared to analysts’ expectations of $26.27 million. Equities research analysts predict that Autolus Therapeutics will post -0.86 EPS for the current fiscal year.

Institutional Investors Weigh In On Autolus Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. GAMMA Investing LLC increased its stake in Autolus Therapeutics by 115.6% during the 2nd quarter. GAMMA Investing LLC now owns 15,499 shares of the company’s stock valued at $25,000 after purchasing an additional 8,309 shares in the last quarter. Hennion & Walsh Asset Management Inc. grew its holdings in shares of Autolus Therapeutics by 2.5% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 451,403 shares of the company’s stock valued at $722,000 after buying an additional 11,197 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Autolus Therapeutics by 41.6% during the second quarter. The Manufacturers Life Insurance Company now owns 38,419 shares of the company’s stock worth $88,000 after acquiring an additional 11,289 shares in the last quarter. Invesco Ltd. raised its holdings in shares of Autolus Therapeutics by 53.3% in the 1st quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock worth $51,000 after acquiring an additional 11,381 shares during the last quarter. Finally, Marex Group plc bought a new position in Autolus Therapeutics in the 2nd quarter valued at about $28,000. Institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics News Roundup

Here are the key news stories impacting Autolus Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its 2026 EPS forecast to a loss of $0.88 from $1.08 and improved estimates for the second, third and fourth quarters of 2026 to losses of $0.22, $0.21 and $0.19 per share, respectively. The firm reiterated its Buy rating and $10 price target, substantially above recent trading levels. HC Wainwright Reiterates Buy Rating for Autolus Therapeutics
• Neutral Sentiment: The revised 2026 quarterly forecasts imply narrower losses than previously expected, while HC Wainwright projects a $0.74-per-share loss in 2027 and continued losses through 2030. Autolus remains unprofitable, so valuation is highly dependent on clinical, commercial and financing progress.
• Negative Sentiment: HC Wainwright cut its longer-term EPS estimates for 2027 to a loss of $0.74 from $0.67, 2028 to a loss of $0.83 from $0.54, 2029 to a loss of $0.69 from $0.38, and 2030 to a loss of $0.23 from $0.20. These reductions suggest profitability may take longer to achieve than previously anticipated.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.